Cushman & Wakefield Recognized by USA TODAY as One of America's Climate Leaders 2025
CHICAGO, May 15, 2025--(BUSINESS WIRE)--Cushman & Wakefield (NYSE: CWK), a leading global real estate services firm, was recognized on USA TODAY's list of America's Climate Leaders 2025. This award is presented by USA TODAY and Statista, the world-leading statistics portal and industry ranking provider.
"We are honored to be recognized as one of America's Climate Leaders by USA TODAY. At Cushman & Wakefield, our commitment to sustainability and driving positive change for our business and our clients remains a top priority," said Jessica Francisco, Cushman & Wakefield's Chief Sustainability Officer. "This award highlights our efforts in reducing carbon emissions for our operations and our dedication to transparent emission reporting. The commercial real estate industry has a unique opportunity to lead in this area, and our proactive measures today will not only contribute to a healthier planet but also enhance our operational efficiency and resilience."
Cushman & Wakefield offers a suite of sustainability service offerings across a range of disciplines to provide seamless, end-to-end solutions for their real estate occupier and investor clients. The firm is committed to helping clients navigate the complex and evolving landscape of environmental responsibility, supporting their clients to reduce operational costs, improve environmental, social and governance performance, and manage climate change risks and opportunities across assets, funds and portfolios.
To qualify for the award, companies must be headquartered in the United States, have a revenue of at least $50 million in 2023, provide independent emission reporting for Scope 1 and 2 emissions from 2021 to 2023, and have at least a C rating from the CDP, if a score is available. To make the list of America's Climate Leaders, companies must also demonstrate a year-to-year reduction in carbon intensity (carbon emissions divided by revenue) of at least 3%.
The full list of featured companies can be found on USA TODAY's website.
Learn more about sustainability at Cushman & Wakefield here.
About Cushman & Wakefield
Cushman & Wakefield (NYSE: CWK) is a leading global commercial real estate services firm for property owners and occupiers with approximately 52,000 employees in nearly 400 offices and 60 countries. In 2024, the firm reported revenue of $9.4 billion across its core service lines of Services, Leasing, Capital markets, and Valuation and other. Built around the belief that Better never settles, the firm receives numerous industry and business accolades for its award-winning culture. For additional information, visit www.cushmanwakefield.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250515538047/en/
Contacts
Media Contact: Annie Wood Corporate Communications+1 817 456 6209annie.wood@cushwake.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
33 minutes ago
- Business Wire
VSTS Investors Have Opportunity to Lead Vestis Corporation Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vestis Corporation ('Vestis' or 'the Company') (NYSE: VSTS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 2, 2024 and May 6, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before August 8, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Vestis misled investors about the actual extent of its ability to grow the business. The Company was not equipped to execute on planned strategic initiatives. The Company struggled to bring in new customers and retain existing customers. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Vestis, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
36 minutes ago
- Yahoo
Walmart drone delivery expands: Service is coming to 5 new US cities
Walmart is expanding its drone delivery service to five more major United States cities, the company announced. The retail corporation is set to offer the amenity in parts of Georgia, Florida, North Carolina and Texas, Walmart wrote in a press release. The company already offered drone delivery in Dallas, Texas and Bentonville, Arkansas. Walmart said it has made more than 150,000 drone deliveries since launching the service in 2021. "This expansion underscores Walmart's commitment to reshaping the future of fast and flexible retail," the release reads. Here is what to know about the service and where it's expanding. Walmart, according to its website, now offers drone delivery in these five new cities: Atlanta Charlotte Houston Orlando Tampa Walmart currently provides drone delivery in Dallas as well as it its headquarters city of Bentonville, Arkansas. Including the expanded sites, Walmart said it will offer drone delivery services at a total of 100 stores. 'This expansion of our drone delivery service marks a significant milestone in that journey," Greg Cathey, senior vice president of Walmart U.S. Transformation and Innovation said in the release. "As the first retailer to scale drone delivery, Walmart is once again demonstrating its commitment to leveraging technology to enhance our delivery offerings with a focus on speed.' Could the tech reach your state? Drones are delivering medical supplies in Massachusetts Walmart encourages those looking to use drone deliveries in Atlanta, Charlotte, Houston, Orlando and Tampa to sign up on Wing to be notified of when the service becomes available in their market. For shoppers in the Dallas-Fort Worth area, Walmart said you can check your eligibility here. Walmart and other big businesses including Amazon began using drone delivery in recent years. Walmart began testing drone delivery in 2020 and the following year, the company announced it invested in drone company DroneUp. Since then, the retailer has continued to offer drone deliveries to more markets and customers. Natalie Neysa Alund is a senior reporter for USA TODAY. Reach her at nalund@ and follow her on X @nataliealund. This article originally appeared on USA TODAY: Walmart drone delivery coming to 5 new US cities: See list Sign in to access your portfolio
Yahoo
36 minutes ago
- Yahoo
2 Weight Loss Drug Stocks That Are Screaming Buys in June
Novo Nordisk and Eli Lilly have most of the GLP-1 drug market to themselves. Based on current pipelines, this state of affairs could continue. Both stocks are attractively priced at the moment. 10 stocks we like better than Novo Nordisk › Is there a hotter trend in healthcare than weight loss drugs? Probably not. Research from Morgan Stanley suggests that sales of weight loss drugs will soar from an estimated $15 billion last year to as much as $150 billion by 2035. That would be a tenfold increase in just over a decade. Most current medications for weight loss are GLP-1 agonists, which suppress patients' appetites by slowing digestion and making them feel full. Two companies, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY), currently dominate this area, together accounting for an estimated 97% of the market share. Can they can stay atop this fast-growing industry? Here's what I found -- and why they could both be screaming buys right now in June 2025. Whenever an opportunity exhibits such rapid growth, it will inevitably attract competition. Indeed, numerous companies are currently developing weight loss drugs. However, it's quite a leap to assume that Novo Nordisk, with 62% of the GLP-1 market, and Eli Lilly with another 35%, will easily cede their market share to new products. First and foremost, drug development is a challenging process that undergoes rigorous regulatory testing. Many of the drugs in development today will ultimately fail to reach the market. In April, industry heavyweight Pfizer abandoned development of its oral weight loss drug danuglipron, after it may have caused a liver injury in a patient during a clinical trial. Weight loss drugs that do make it to market must then actually compete with what patients already use. That boils down to more than price: Efficacy, side effects, and prescribers' comfort levels with products all make a difference in how these treatments ultimately sell. The weight loss opportunity is currently in its early innings. The leading drugs -- Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound -- are injected, require refrigeration, and remain expensive for patients. Upcoming drugs will include more convenient oral pills; some could be cheaper to produce, and thus could be sold at lower prices. Naturally, Novo Nordisk and Eli Lilly have remained active in order to stay atop the market. Novo Nordisk could soon have an oral GLP-1 agonist for sale; it has filed an application for approval of an oral version of Wegovy. The company hopes to receive a nod by the end of this year. Additionally, its candidate CagriSema, a potential successor to Wegovy, is working through phase 3 trials. At this rate, CagriSema could arrive sometime next year. Eli Lilly is also very active. Its experimental oral weight loss drug, orforglipron, has performed well in phase 3 studies. It could be the first small-molecule drug to hit the market; small-molecule drugs are easier and cheaper to manufacture. Its next-generation injectable therapy, retatrutide, is innovative in that it targets three separate hormones related to hunger. Retatrutide is also currently in phase 3 studies, and could arrive in 2027 if all goes well. Boehringer Ingelheim's survodutide, an injected therapy that could arrive in 2027, is arguably the only potential near-term competition worth noting. There aren't any other immediate threats to Novo Nordisk and Eli Lilly's dominance. The next hopeful, MariTide from Amgen, only begins phase 3 studies in March; if approved, its estimated market arrival would be in 2028. Barring something unexpected, Novo Nordisk and Eli Lilly appear well positioned to capture much of that explosive growth in the weight loss market over the coming years. The question is, which industry giant will do better? Wall Street is currently placing its money on Eli Lilly, as evidenced by the stock's significant valuation premium. Shares trade at a price-to-earnings (P/E) ratio of 62, versus just 22 for Novo Nordisk. Novo Nordisk's CagriSema has struggled to outperform existing treatments in clinical trials, while Eli Lilly's orforglipron has performed well. However, how patients choose treatments involves several factors, so it's not a sure thing that Eli Lilly will capture all this market share from Novo Nordisk. The best solution? Own both. One way to value them is by their PEG ratios, which weigh the stocks' valuations against the companies' expected growth rates: Novo Nordisk PEG ratio: 1.5 Eli Lilly PEG ratio: 1.9 Both companies are reasonably priced for their expected long-term earnings growth, currently 14% annualized for Novo Nordisk and 32% annualized for Eli Lilly. Of course, that could play out differently, but it's all the more reason to own both stocks. One way or another, these two companies will likely split the upside in the weight loss drug market. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen and Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Weight Loss Drug Stocks That Are Screaming Buys in June was originally published by The Motley Fool
